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Background: Snakebite is considered a neglected tropical disease by the World Health Organization. In Brazil,
about 70% of the envenomation cases are caused by Bothrops snakes. Its venom may provoke hemorrhage, pain,
necrosis, hemolysis, renal or cardiac failure and even death in victims. Since commercial antivenom does not
efficiently neutralize the local toxic effects of venoms, natural products have been tested in order to provide
alternative or complementary treatment to serum therapy. Therefore, the present study aimed to evaluate the
ability of the seaweed Plocamium brasiliense and its active derivatives to neutralize hemorrhagic, edematogenic,
hemolytic, coagulant and proteolytic activities of B. jararaca venom.
Methods: Specimens of P. brasiliense were collected in Rio de Janeiro state, Brazil, dried and submitted to oil
extraction using four solvents of increasing polarities, n-hexane (HEX), dichloromethane (DCM), ethyl acetate (ETA)
and hydroalcoholic solution (HYD). The solvents were evaporated, yielding HEX, DCM, ETA and HYD extracts.
Further, all extracts were dissolved in dimethylsulfoxide. In addition, two monoterpenes (8-bromo-3,4,7-trichloro-3,7-
dimethyl-1E, 5E-octadiene and 1,8-dibromo-3,4,7-trichloro-3,7-dimethyl-1E, 5E-octadiene) and a cholesterol fraction
were isolated from the extract of P. brasiliense prepared in hexane. Algal samples were incubated for 30 minutes
with B. jararaca venom, and then tested for lethality; hemorrhagic, edematogenic, hemolytic, coagulant and
proteolytic effects.
Results: Most of the algal extracts inhibited the toxic effects with different potencies. The DCM extract was the
most effective, since it inhibited all types of toxic activity. On the other hand, the HYD extract failed to inhibit any
effect. Moreover, the isolated products inhibited proteolysis and protected mice from hemorrhage in 30% of the
cases, whereas 8-bromo-3,4,7-trichloro-3,7-dimethyl-1E, 5E-octadiene inhibited 100% and 20% of the hemorrhagic
and proteolytic activities, respectively. None of the algal products were toxic to mice.
Conclusion: Seaweeds may be a promising source of inhibitors against toxic effects caused by B. jararaca
envenomation, which may contribute to antivenom treatment.
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Snakebites comprise a serious health problem in numer-
ous parts of the world, due to their seriousness, sequelae
and high fatality rates. According to the World Health
Organization [1], up to five million people are bitten by
snakes every year, and around 2 million of these people
die, whereas 400,000 cases end in amputations and other* Correspondence: andfuly@vm.uff.br
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unless otherwise stated.severe health consequences, such as infection, tetanus,
scarring, contractures, and psychological sequelae [1,2].
According to Kasturiratne et al. [3], 420,000 to 1,841,000
snakebites occur per year worldwide with 20,000 to 94,000
deaths. However, research indicates that the burden of
envenomation by snakes may be even heavier.
In Brazil, snakes of the Bothrops genus are involved
in most cases of human envenomation, about 70%, par-
ticularly the species B. jararaca [4,5]. Bothrops venoms,
which have been extensively studied, are composed of a
complex mixture of proteins, peptides and other organicl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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necrosis, inflammation, hemorrhage) and systemic (coagu-
lation disturbances, renal and cardiac failure) effects in
victims [6-13]. B. jararaca is found in southern Brazil,
Paraguay, and northern Argentina. Envenomation by this
species has a similar profile to that observed in other
Bothrops species including shock, tissue necrosis, intra-
vascular coagulation, local and systemic hemorrhage and
edema.
The recommended treatment for envenomation by
this species is polyvalent Bothrops antivenom, which is
produced by horse hyperimmunization [14-16]. In spite
of inhibiting systemic toxic effects, antivenom has a few
disadvantages including ineffectiveness against local ef-
fects and side effects [17-19]. In addition, the variability
in venom composition of different Bothrops species may
affect the antivenom efficacy. Therefore, alternative stra-
tegies and treatments have been extensively investiga-
ted [20,21]. In most developing countries, about 80% of
snakebite victims seek help first from traditional practi-
tioners that use plant extracts. Appropriate medical care
with antivenom therapy is usually their second option
[21]. Thus, natural products are good candidates for al-
ternative treatments. The seas provide an amazing source
of molecules when compared to the terrestrial environ-
ment; however, little is known about their biological or
pharmacological functions. Marine organisms produce
molecules derived from primary and secondary metab-
olism with biological and pharmacological effects, such
as antiviral, anticancer, anticoagulant and antiplatelet ac-
tivities [22-26]. Previously, antivenom activity has been de-
scribed in marine algae and sponges, which showed that
both organisms can inhibit some toxic effects of Lachesis
muta and B. jararaca venoms [27,28].
In the present study, the red seaweed Plocamium
brasiliense (Greville) M. Howe and W.R. Taylor has
been investigated. The genus Plocamium Lamouroux
(Plocamiaceae, Rhodophiceae) contains more than 40
species that are widely distributed over the oceans. P.
brasiliense is abundant off the east-southeast coast of
Brazil [29]. These marine algae produce acyclic and cyclic
halogenated monoterpenes, of which more than 100 mol-
ecules have been isolated [29,30]. Such molecules have
shown biological activities including antimicrobial, anti-
fungal, ichthyotoxic, cytotoxic and insecticidal properties
as well as antiviral activity against herpes virus [31,32].
Moreover, P. brasiliense may be used as herbicide or even
as food [33]. It has been shown that three products
isolated from P. brasiliense inhibited some toxic in vitro
and in vivo activities of B. jararaca venom: monoterpene
1 (8-bromo-3,4,7-trichloro-3,7-dimethyl-1E, 5E-octadiene),
monoterpene 2 (1,8-dibromo-3,4,7-trichloro-3,7-dimethyl-
1E, 5E-octadiene) and a cholesterol [30,32,34]. Their
chemical structures are shown in Figure 1.The aim of the present study was to evaluate the in-
hibitory potential of extracts of P. brasiliense and of their
isolated products (the two monoterpenes and cholesterol)
against some in vitro (proteolysis, coagulation and
hemolysis) and in vivo (hemorrhage, lethality and edema)
toxic effects induced by B. jararaca snake venom.
Methods
Algal material
Specimens of P. brasiliense were collected by snorkeling
in October 2010, at Enseada do Forno beach, in the city
of Armação de Búzios, located in the north of Rio de
Janeiro state, Brazil (22° 45′ S, 41° 52′ W). They were
washed with local seawater and separated from sedi-
ments, epiphytes and other associated organisms. The
algae were dried for twenty days and their extracts were
obtained by using appropriate solvent. Voucher speci-
mens were deposited in the Herbarium of the Rio de
Janeiro State University (HRJ 10331–32). The Brazilian
algal collection license (VLT) number is 10594 (IBAMA/
SISBIO).
Preparation of crude extracts and fractions
P. brasiliense was collected and dried at room tem-
perature (average of 28°C). Then, the algal crude extract
was ground in an industrial blender and placed into a
plastic tray, yielding 5.16 g of powdered algae. P. brasi-
liense oil extraction was performed using the solvents
hexane, dichloromethane, ethyl acetate and ethanol/water.
Afterwards, all solvents were evaporated off under re-
duced pressure, yielding a crude residue. An aliquot of
each extract was weighed, aliquoted and frozen at −20°C,
and finally, the extracts were dissolved in dimethylsulfox-
ide (DMSO, 30% v/v) to perform the biological assays.
The extracts were obtained according to Fonseca et al.
[31] and yielded the following values: n-hexane, 500 mg;
dichloromethane, 196 mg; ethyl acetate, 42 mg; and
ethanol/water, 250 mg. The extract prepared in n-hexane
(500 mg) was subjected to silica gel 70–230 mesh col-
umn chromatography (4 × 70 cm) eluted with n-hexane,
CH2Cl2, EtOAc and MeOH in sequence, resulting in 97
fractions of 10 mL each (F1 to F97) and 55 fractions of
20 mL each (F98 to F153). The fraction F17 (18 mg)
eluted with n-hexane/CH2Cl2 (9.7:0.3) and the fraction
F76 (16 mg) eluted with n-hexane/CH2Cl2 (5:5) con-
tained the pure halogenated monoterpenes 1 and 2,
respectively. The fractions F112 to F118 eluted with
n-hexane/CH2Cl2 (3.5:6.5) and F119-F125 eluted with
n-hexane/CH2Cl2 (3:7) contained the pure cholesterol
(42 mg). These fractions were also obtained according
to the method by Fonseca et al. [31], and were analyzed
according to Vasconcelos et al. [30] by HRGC/MS on a
HP 5890 series GC system, coupled to a HP 5973 mass
selective detector in the EI mode (70 eV) equipped with
Figure 1 Chemical structure of (1) monoterpene 1 (8-bromo-3,4,7-trichloro-3,7-dimethyl-1E,5E-octadiene), (2) monoterpene 2
(1,8-dibromo-3,4,7-trichloro-3,7-dimethyl-1E,5E-octadiene) and of the (3) cholesterol fraction.
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thickness 0.25 μm), and dissolved in DMSO (30%, v/v)
as well.
Venom and animals
B. jararaca venom was kindly supplied by the Ezequiel
Dias Foundation (FUNED), Belo Horizonte, Minas Gerais
state, Brazil, vacuum dried and stored at −20°C until
use. Male Balb/c mice (Mus musculus species) weighting
18–20 g were obtained from the Center of Laboratory
Animals (NAL) of the Federal Fluminense University
(UFF). They were housed under controlled conditions
of temperature (24 ± 1°C) and light. All the experiments
performed were approved by the UFF Institutional Com-
mittee for Ethics in Animal Experimentation (CEUA:
200/10) and were in accordance with the guidelines of
the Brazilian Committee for Animal Experimentation
(COBEA).
Antihemolytic activity
The degree of hemolysis of B. jararaca venom was de-
termined by the indirect hemolytic test using human
erythrocytes and hen’s egg yolk emulsion as substrates
[35]. The lowest amount of B. jararaca venom that pro-
duced 100% hemolysis was called the minimum indirect
hemolytic dose (MIHD). Inhibitory experiments were
performed by incubating algal extracts with one MIHDfor 30 minutes at room temperature, and then, hemo-
lytic activity was evaluated. Positive controls were per-
formed by incubating venom with DMSO (5% v/v) or
saline solution, instead of extracts. DMSO (5% v/v) or
extracts alone were used as negative controls.
Anticoagulant activity
The coagulant activity of B. jararaca venom was mo-
nitored using a digital Amelung coagulometer, model
KC4A (Labcon, Germany). Different concentrations of
B. jararaca venom were mixed with diluted citrated
plasma (1:1 in saline) donated from healthy volunteers
collected at a local public blood bank (University Hospital
Antônio Pedro of UFF). The amount of venom (μg/mL)
that clotted plasma in 60 seconds was called the minimum
coagulant dose (MCD). To evaluate the inhibitory effect,
algal extracts were incubated for 30 minutes at room
temperature with one MCD, and then, the mixture was
added to plasma and coagulation time was recorded. Posi-
tive controls were performed in parallel by incubating
venom with DMSO (1% v/v) or saline solution. DMSO
(1% v/v) or extracts alone were used as negative controls.
Antiproteolytic activity
Proteolytic activity of B. jararaca venom was determined
using azocasein as substrate (0.2% w/v, in 20 mM Tris–HCl,
8 mM CaCl2, pH 8.8) [36] – with minor modifications. An
Figure 2 Effect of P. brasiliense on plasma coagulation of B.
jararaca venom. The venom (20 μg/mL) was incubated with algal
extracts (100 μg/mL) prepared in n-hexane (group I), dichloromethane
(group II), ethyl acetate (group III) or hydroalcoholic solution (group IV),
then the mixtures were added to plasma and coagulation was
monitored. Control groups consisted of venom incubated with NaCl
(C1) or with DMSO (C2). Results are expressed as mean ± SE of two
individual experiments (n = 3). *p < 0.05 when compared to C1 or C2.
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of B. jararaca venom (μg/mL) able to produce a vari-
ation of about 0.2 OD units at A 420 nm (spectropho-
tometer Hitachi U-5100). The inhibitory effect of algal
extracts was performed by incubating them with two
EC of B. jararaca venom for 30 minutes at room
temperature and then, proteolysis was measured. Simi-
larly, control experiments were conducted by mixing
venom with DMSO (5% v/v) or saline solution and, fur-
ther proteolysis was performed. DMSO (5% v/v) or ex-
tracts were used as negative controls.
Antihemorrhagic activity
Hemorrhagic lesions produced by B. jararaca venom
were quantified using a procedure described by Kondo
et al. [37] with modifications. Briefly, samples (100 μL)
were injected intradermally (i.d.) into abdominal skin of
mice. Two hours later, the animals were euthanized,
abdominal skin was removed, stretched and inspected
for visual changes in the inner surface of subcutaneous
layers in order to find hemorrhagic spots. Hemorrhage
was classified into minimum hemorrhagic dose (MHD),
defined as the amount of B. jararaca venom (μg/g) able
to produce a hemorrhagic halo of 10 mm [38]. The in-
hibitory effect of algal extracts was investigated by incu-
bating them with two MHD of B. jararaca venom for
30 minutes at room temperature and then, the mixture
(100 μL) was injected i.d. into mice and hemorrhage was
observed. Hemorrhagic activity was expressed as the
mean diameter (in millimeters) of the hemorrhagic halo
induced by B. jararaca venom in the absence and pres-
ence of algae. Negative controls were performed by injec-
ting only DMSO (5% v/v), extracts or saline solution.
Antiedematogenic activity
Edema-inducing activity of B. jararaca venom was deter-
mined according to Yamakawa et al. [39]. Groups of five
mice received 50 μL of B. jararaca venom subcutane-
ously (s.c.) in the right paw, while the left paw received
50 μL of saline solution or DMSO. One hour after injec-
tion, edema was evaluated as the percentage increase in
weight of the right paw compared to the left one. Antie-
dematogenic activity was performed by incubating algal
extracts with B. jararaca venom for 30 minutes at room
temperature, and then the mixture was injected s.c. into
mice. Control experiments were performed by mixing B.
jararaca venom with DMSO (5% v/v) or saline solution.
For negative controls, DMSO (5% v/v) or extracts were
injected.
Anti-lethal activity
Groups of six mice received (100 μL) intraperitoneally
(i.p.) B. jararaca venom (20 μg/g) and were observed
for 48 hours. The anti-lethal assay was performed byincubating B. jararaca (20 μg/g) with algal extracts
(80 μg/g) for 30 minutes at room temperature and the
mixture was injected i.p. into mice. Positive control
groups received B. jararaca mixed with saline solution
or DMSO, and negative controls received algal extracts
instead of venom.
Statistical analysis
Results are presented as means ± S.E.M. The statistical
significance of differences between tests was evaluated
by Student’s unpaired t-test. p values of < 0.05 were con-
sidered statistically significant.
Results
Effect of P. brasiliense extracts on B. jararaca
venom-induced coagulation
B. jararaca venom (20 μg/mL) clots plasma usually in
70 seconds. Therefore, this venom concentration was
mixed with P. brasiliense extracts (100 μg/mL) in order
to evaluate the effects on coagulation (Figure 2). As shown
in Figure 2, the algal extracts inhibited the coagulant ac-
tivity of B. jararaca venom in different degrees. The ex-
tracts prepared in dichloromethane (Figure 2, group II)




B. jararaca +monoterpene 1 20 ± 4.5 100
B. jararaca +monoterpene 2 37 ± 2.1 32 ± 11
B. jararaca + cholesterol 33 ± 2.5 28 ± 6
Monoterpene 1: 8-bromo-3,4,7-trichloro-3,7-dimethyl-1E,5E-octadiene;
monoterpene 2: 1,8-dibromo-3,4,7-trichloro-3,7-dimethyl-1E,5E-octadiene.
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more and less efficiently, respectively. When tested alone,
the extracts did not induce coagulation.
Effect of P. brasiliense extracts on B. jararaca
venom-induced proteolysis
P. brasiliense extracts (10 and 100 μg/mL) inhibited the
proteolytic activity of 10 μg/mL of B. jararaca venom
(Figure 3). Regardless of the concentration, the dichlo-
romethane extract had the highest inhibitory activity
(Figure 3, group II), while the hydroalcoholic solution
did not inhibit at all (Figure 3, group IV). The other two
extracts (n-hexane, group I, and ethyl acetate, group III,
at 100 μg/mL) inhibited proteolysis by 57% and 84%,
respectively. In addition, the monoterpenes 1 and 2
inhibited by 20% and 38%, respectively, while the choles-
terol inhibited proteolysis induced by B. jararaca venom
by 32% (Table 1). The extracts alone were not able to
hydrolyze azocasein.
Effect of P. brasiliense extracts on B. jararaca
venom-induced hemolysis
The extracts were not able to lyse erythrocytes. However,
the hemolysis caused by B. jararaca venom (30 μg/mL)Figure 3 Effect of P. brasiliense extracts on proteolysis induced
by B. jararaca venom. P. brasiliense extracts (10 μg/mL, white
columns) and (100 μg/mL, black columns) prepared in n-hexane
(group I), dichloromethane (group II), ethyl acetate (group III) or
hydroalcoholic solution (group IV) were incubated with B. jararaca
venom (10 μg/mL). Results are expressed as mean ± SE of two
individual experiments (n = 3).was inhibited significantly by all P. brasiliense extracts
(90 and 180 μg/mL), except for the hydroalcoholic solu-
tion (Figure 4). The extract prepared in dichloromethane
inhibited hemolysis by 88% and 98%, at 1:3 and 1:6 ve-
nom:algae ratios (w/w), respectively (Figure 4, group II).
At both venom:algae ratios, the ethyl acetate extract in-
hibited proteolysis by 25% (Figure 4, group III).
Effect of P. brasiliense extracts on B. jararaca
venom-induced hemorrhage, edema and lethality
P. brasiliense extracts prepared in different solvents and their
isolated products inhibited hemorrhage and edematogenicFigure 4 Effect of P. brasiliense extracts on hemolysis provoked
by B. jararaca venom. Different concentrations of P. brasiliense
algal extracts (90 μg/mL, white columns or 180 μg/mL, black
columns) prepared in n-hexane (group I), dichloromethane (group
II), ethyl acetate (group III) or hydroalcoholic solution (group IV) were
incubated with B. jararaca venom (30 μg/mL). Results are expressed
as mean ± SE of two individuals experiments (n = 3).
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extracts (15 μg/mL) prepared in n-hexane (group I), di-
chloromethane (group II) and ethyl acetate (group III)
fully inhibited B. jararaca venom-induced hemorrhage,
except for the one prepared in hydroalcoholic solution
(group IV) (Figure 5A). The isolated products from P.
brasiliense (15 μg/mL) monoterpene 2 and cholesterol
inhibited hemorrhagic activity of B. jararaca venom by
30%, while the monoterpene 1 inhibited 100% hemorrhage
(Table 1).
Edema provoked by B. jararaca venom was also inhib-
ited by the extracts of P. brasiliense (Figure 5B). Those
prepared in dichloromethane (Figure 5B, group II) and
ethyl acetate (Figure 5B, group III) inhibited edema by
22%, while extracts in hexane and hydroalcoholic solu-
tion inhibited by 15% and 2%, respectively (Figure 5B).
Mice injected with B. jararaca venom (20 μg/g) died
in about 10 hours. Incubation of venom with derived
products (80 μg/g) did not protect the animals against
the lethal effects of B. jararaca venom (data not shown).
When algal extracts alone, products or vehicle (DMSO
or saline) were injected into animals, no hemorrhage,
edema or death was seen. Therefore, extracts and derived
products were not toxic to mice.
Discussion
Envenomation resulting from snakebites is a particularly
important public health problem in rural areas of trop-
ical and subtropical countries [1,2]. In Brazil, according
to the registers of the Brazilian Ministry of Health, about
30,000 victims are envenomated per year with hundreds
of deaths [1,4,40,41]. However, these numbers are not ac-
curate since snakebites often occur in areas where there isFigure 5 Effect of P. brasiliense extracts on hemorrhage and edema in
in n-hexane (group I), dichloromethane (group II), ethyl acetate (group III) a
venom (25 μg/g). Then, mixtures were injected into mice and hemorrhagic
described in methods. Results are expressed as mean ± SE of two individuano health unit or hospital to record the case. Snakebite is
a neglected tropical disease; hence, little attention has
been given by the pharmaceutical industry, governments
and academia to improve antivenom therapy.
In Brazil, antivenom is the only treatment available
against snakebites, but it has some limitations and dis-
advantages. Therefore, alternative treatments, including
natural products, have been investigated to complement
or to replace antivenom therapy. Plant extracts have
been used in folk medicine to treat or to ameliorate sev-
eral conditions, including snakebites, and many scientific
reports have proven their efficacy [21,42]. In contrast,
the research on marine algae as inhibitors of toxic effects
of snake venoms is limited. Previous results from our
group have shown the inhibitory activity of plants, mar-
ine sponges and seaweed against snake venoms, but little
is known about antivenom properties of algae such as
P. brasiliense [28,43-45]. An initial study was conducted
by Claudino et al. [34] analyzing the inhibitory action
of P. brasiliense extract against the toxic effects of
L. muta snake venom. Apart from antivenom activities,
some biological and pharmacological properties have
been found in these algae and their derived products,
such as defense against marine herbivores and antiviral
activity [31,32].
In the present work, we showed that P. brasiliense
crude extracts – prepared in n-hexane (HEX), dichloro-
methane (DCM), ethyl acetate (ETA) and hydroalcoholic
solution (HYD) – and three isolated products from HEX
fractions (two halogenated monoterpenes and a choles-
terol) inhibited in vivo and in vitro activities induced by B.
jararaca venom. All the solvents employed are of increa-
sing polarities, therefore they able to extract moleculesduced by B. jararaca venom. The algal extracts (35 μg/g) prepared
nd hydroalcoholic solution (group IV) were incubated with B. jararaca
(Panel A) or edematogenic (Panel B) activities were analyzed, as
ls experiments (n = 3).
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larity solvent DCM inhibited most activities of B. jararaca
venom whereas HYD, with the highest polarity solvent, re-
corded no inhibitory activity.
B. jararaca venom is rich in serine proteinases, metal-
loproteinases, phospholipases and phosphoesterases that
affect the nervous system, blood coagulation, muscle tis-
sue, red blood cells and other organs [46]. Furthermore,
these enzymes are directly involved in local effects that
are responsible for amputations and deformities as well
as in systemic symptoms in victims [47]. B. jararaca
venom induces coagulation, and thrombin-like enzymes
participate in such action, leading plasma to clot and
venom-induced consumptive coagulopathy. DCM, in
particular, inhibited coagulation induced by B. jararaca
venom, preventing fibrin production. However, it is un-
known whether DCM extract interacts with compo-
nents of the intrinsic and/or extrinsic pathways of the
coagulation system. Moreover, DCM, HEX and ETA
prevented proteolytic activity of B. jararaca venom, so
that they may be interacting with proteases in such
venom. In contrast, the extract prepared in HYD failed
to inhibit proteolysis and coagulation provoked by B.
jararaca venom. The two monoterpenes and the choles-
terol fraction inhibited proteolysis of B. jararaca venom.
The crude extracts of P. brasiliense and the isolated
products protected mice from hemorrhage and edema,
except for HYD extract. The monoterpene 2 and the
cholesterol derivatives inhibited around 30% of hemor-
rhage, whereas the monoterpene 1 fully inhibited it.
Hemorrhagic activity of venoms is due to the action of
metalloproteases and phospholipases A2 (PLA2). Several
symptoms of envenomation by snakes such as coagulation
and hemorrhage are associated with such enzymes, and
they are one of the major groups of enzymes that cause
the deleterious effects of venoms in victims [48,49]. The
antivenom properties of extracts and derived products
may be related to an inhibitory action upon such key en-
zymes. In the literature, many hypotheses have been pro-
posed as mechanisms of inhibitory action of plants as well
as any other natural sources, as protein precipitation, en-
zyme inactivation, metal chelation and antioxidant effect.
However, the mechanism by which neutralization occurs
is unknown [50].
In addition to hemorrhage, edematogenic activity should
be considered in envenomation. It may be caused by the
action of PLA2s that are poorly inhibited by commercial
antivenoms [51]. PLA2s are calcium-dependent enzymes
from venoms that induce edema, myotoxicity and lysis of
the red blood cells, and these effects may contribute to
morbidities or disabilities frequently observed in B. jara-
raca envenomation [52]. The DCM (98%) and HEX (60%)
extracts effectively inhibited hemolysis. In the literature,
researchers have made efforts in order to neutralize PLA2enzymes, providing protection against snakebite symp-
toms. In this regard, edema induced by B. jararaca venom
was inhibited by the extract of P. brasiliense as well in the
present study. PLA2s also participate in the formation of
lysolecithin (also called lysophosphatidylcholine), which is
formed by the hydrolysis of phospholipids. Moreover, the
toxic action of lysolecithin formed by the action of PLA2s
from other sources of venoms has also been investigated.
A PLA2 isolated from L. muta venom modulates natural
killer activity by the protein kinase C pathway [53]. B.
jararaca venom contains several isoenzymes of PLA2,
serine proteases and metalloproteases that cause edema,
coagulation and hemorrhage, respectively. However, any
inhibitory effect cannot be attributed just to a specific
group of enzymes since DCM and HEX extracts and mo-
noterpene 1 fully inhibited all these toxic activities. It is
worth noting that the less polar fractions, DCM and HEX,
inhibited the toxic activities of B. jararaca venom more ef-
fectively, while the more polar, HYD did not inhibit such
activities.
These products derived from P. brasiliense could be
useful for treating the local effects induced by B. jara-
raca venom, since antivenom is not fully effective in pre-
venting them, leading snakebite victims to amputations.
To produce a single molecule or extract able to inhibit
all the toxic activities of snake venom is a challenge as is
developing an effective treatment, since there are onto-
genetic variations in snake venom of B. jararaca [54]. B.
jararaca venom, or any other snake venom, has different
domain composition, glycosylation patterns and tertiary
or quaternary structure, thus displaying different toxicity
profiles and different or variable susceptibilities to in-
hibitors [55]. This fact greatly increases the difficulty in
obtaining an entirely effective molecule able to fully
neutralize the toxic effects and symptoms of envenom-
ation by snakes. However, natural products such as the
algal extracts described in the present paper provide
hope for the future.
Marine seaweed produce biologically active molecules
that have several pharmacological effects. In the present
study, P. brasiliense extracts and three isolated products
neutralized the main harmful effects of B. jararaca venom,
both systemic (hemolysis, coagulation and hemorrhage)
and local (edema and hemorrhage) symptoms observed in
snakebite victims. However, venom-induced lethality was
not prevented by algal extracts. In our opinion, the inef-
fectiveness concerning lethal outcomes should not be con-
sidered a discouraging result, since antivenom therapy
efficiently neutralizes it [51]. In conclusion, these extracts
have potential to be used to complement treatment of vic-
tims of B. jararaca envenomation. The present research
aims to stimulate the development of new antivenom
drugs based on further studies on algal and other natural
products.
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The crude extracts of P. brasiliense and their isolated
products inhibited in vivo and in vitro some harmful ef-
fects induced by the venom of B. jararaca. Therefore,
these marine algae have biotechnological potential to
lead to the development of alternative or complementary
therapy for snake envenomation caused by B. jararaca.
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